



Working with your company's preclinical R & D needs

XENOGRAFT MODELS

Cell lines offered:

Prostate: PC3, DU145, LNCaP, 22Rv1

Breast: BT474, MCF7, SKBr3, BT 483

Colorectal: HT29, Colo320DM, Colo205, HCT15, DLD1, SNU C2B, NCI H716, HCT-116

Lung: NCI H460, A549, NCI-H226

Melanoma: WM115, A375

Ovarian: SK-OV3, OvCAR3

Pancreatic: BxPC3

Glioblastoma: A172

Hematopoietic:

MV-4-11/MOLT4/K562/U937/RPMI/CCRF-CEM/HL-60/RAJI/Daudi

Sample experimental design

Day 1 Inject cells of interest into flank of *nu/nu* mice

Day 15 14 days post implants mice will be dosed either i.p. or p.o. q.d. x 14days. Tumors volume measured twice weekly

Day 28 2 hours post last morning dosing animals will be sacrificed, tumors measured weighed and formalin fixed, paraffin embedded, frozen or processed for other analyses

Sample study (3 group)

XENOGRAFT SETUP - Inject 25 mice into left flanks as described above

COMPOUND TESTING

G1: 5-7 mice, vehicle treatment (IP)

G2: 5-7 mice, Rx-1 @ X mg/kg at a dose volume of 10 μ l/g body weight

G3: 5-7 mice, Rx-2 @ X mg/kg at a dose volume of 10 μ l/g body weight

Tumors will be excised and weighed, then placed in fixative for paraffin embedded processing



Estimate \$11,000

NextGen Pharma Technologies, Inc. • 1235 Lake Plaza Drive, Ste. 134 • Colorado Springs, CO 80906

Phone: (719) 540-2888 • Fax: (719) 540-5003

www.nextgenpharma.com